The strong revenue growth and raised guidance suggest continued momentum in BRUKINSA's global expansion. Traders should monitor upcoming regulatory milestones for Sonrotoclax and TEVIMBRA, which could provide additional catalysts. The significant improvement in profitability and cash flow generation indicates strong operating leverage.
ONC drugs
ONC drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $322.37entry
- T+1 · 9mo ago −1.67%α −1.22% · $316.99
- T+5 · 9mo ago −9.13%α −8.00% · $292.94
- T+20 · 8mo ago −14.09%α −7.69% · $276.95
- T+60 · 6mo ago −3.96%α −11.71% · $309.62
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BeOne Medicines reported strong Q4 and full-year 2025 financial results, with total global revenues of $1.5 billion and $5.3 billion, representing 33% and 40% year-over-year growth, respectively. Diluted GAAP earnings per ADS were $0.58 for Q4 and $2.53 for the full year. The company raised its full-year 2026 revenue guidance to $6.2-$6.4 billion, driven by BRUKINSA's global leadership and continued expansion.
Key Financial Metrics
Key Facts
- Total global revenues of $1.5 billion for Q4 2025, up 33% YoY
- Total global revenues of $5.3 billion for full year 2025, up 40% YoY
- Diluted GAAP EPS of $0.58 for Q4 2025 and $2.53 for full year 2025
- Full year 2026 revenue guidance of $6.2-$6.4 billion
- BRUKINSA global sales of $1.1 billion in Q4 2025, up 38% YoY
- Free cash flow of $941.7 million for full year 2025
Financial Impact
Revenue growth of 33-40% YoY, with 2026 guidance of $6.2-$6.4 billion
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| BRUKINSA | $3.9B | +49.0% |
| TEVIMBRA | $737.0M | +19.0% |
| Amgen in-licensed products | $486.0M | +33.0% |
Risk Factors
- Forward-looking statements about 2026 guidance are subject to significant uncertainties
- Dependence on continued success and market acceptance of BRUKINSA
- Potential regulatory delays for new drug approvals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-011941 |
| Document: bgne-20260226.htm | 0001628280-26-011941 |
| Document: 0001628280-26-011941-index-headers.html | 0001628280-26-011941 |
| Document: 0001628280-26-011941-index.html | 0001628280-26-011941 |
| Document: 0001628280-26-011941.txt | 0001628280-26-011941 |
| CONTEXT: Previous Earnings (2026-02-26) | 0001628280-26-011941 |
Track record
27 reports on ONC
3 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +12.55% at T+60 after the Aug 5, 2026 report. 4 of 6 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $416.54 Now $411.29 −1.26% settles Nov 23
- Nov 10, 20266d ago Insider Cluster Neutral 3/10 Entry $419.98 Now $411.29 −2.07% settles Nov 18
- Nov 6, 202610d ago 144 Neutral 2/10 Entry $417.33 to $411.29 Now $411.29 −1.45% ▼ −1.45% +0.25% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $406.96 to $416.54 Now $411.29 +1.06% ▲ +2.35% −0.24% vs SPY
- Nov 5, 202611d ago 8-K Bullish 6/10 Entry $387.25 to $415.96 Now $411.29 +6.21% ▲ +7.41% +4.12% vs SPY
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $377.78 to $419.98 Now $411.29 +8.87% ▲ +11.17% +12.08% vs SPY
- Oct 2, 20266w ago Insider Cluster Bearish 5/10 Entry $361.65 to $350.40 Now $411.29 −13.73% ▲ +3.11% +3.53% vs SPY
- Sep 22, 20267w ago Institutional Cluster Mixed 4/10 Entry $368.08 to $365.27 Now $411.29 +11.74% ▼ −0.76% +0.42% vs SPY
- Sep 10, 20269w ago Insider Cluster Neutral 3/10 Entry $346.51 to $350.84 Now $411.29 +18.69% ▲ +1.25% +1.47% vs SPY
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $358.26 to $353.83 Now $411.29 +14.80% ▼ −1.24% −0.03% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers